These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29190681)

  • 1. Correction: Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.
    PLOS ONE Staff
    PLoS One; 2017; 12(11):e0189039. PubMed ID: 29190681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.
    Andrade AL; Afonso ET; Minamisava R; Bierrenbach AL; Cristo EB; Morais-Neto OL; Policena GM; Domingues CMAS; Toscano CM
    PLoS One; 2017; 12(9):e0184204. PubMed ID: 28880953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance.
    Sgambatti S; Minamisava R; Bierrenbach AL; Toscano CM; Vieira MA; Policena G; Andrade AL
    Vaccine; 2016 Jan; 34(5):663-670. PubMed ID: 26706272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
    PLoS One; 2019; 14(2):e0212957. PubMed ID: 30789959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
    Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
    PLoS One; 2016; 11(5):e0155088. PubMed ID: 27168324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.
    PLOS ONE Staff
    PLoS One; 2021; 16(7):e0254616. PubMed ID: 34242373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonia in Elderly Australians: Reduction in Presumptive Pneumococcal Hospitalizations but No Change in All-Cause Pneumonia Hospitalizations Following 7-Valent Pneumococcal Conjugate Vaccination.
    Menzies RI; Jardine A; McIntyre PB
    Clin Infect Dis; 2015 Sep; 61(6):927-33. PubMed ID: 26066319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.
    Simonsen L; Taylor RJ; Schuck-Paim C; Lustig R; Haber M; Klugman KP
    Lancet Respir Med; 2014 May; 2(5):387-94. PubMed ID: 24815804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule.
    Becker-Dreps S; Blette B; Briceño R; Alemán J; Hudgens MG; Moreno G; Ordoñez A; Rocha J; Weber DJ; Amaya E
    PLoS One; 2017; 12(8):e0183348. PubMed ID: 28813518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012.
    Griffin MR; Mitchel E; Moore MR; Whitney CG; Grijalva CG;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(44):995-8. PubMed ID: 25375070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines.
    Chuck AW; Jacobs P; Tyrrell G; Kellner JD
    Vaccine; 2010 Jul; 28(33):5485-90. PubMed ID: 20554066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
    Madhi SA; Kuwanda L; Cutland C; Klugman KP
    Clin Infect Dis; 2005 May; 40(10):1511-8. PubMed ID: 15844075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
    Fitzwater SP; Chandran A; Santosham M; Johnson HL
    Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program.
    Moreira M; Cintra O; Harriague J; Hausdorff WP; Hoet B
    Vaccine; 2016 May; 34(25):2766-78. PubMed ID: 27113162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.
    Becker-Dreps S; Amaya E; Liu L; Moreno G; Rocha J; Briceño R; Alemán J; Hudgens MG; Woods CW; Weber DJ
    Pediatr Infect Dis J; 2014 Jun; 33(6):637-42. PubMed ID: 24445827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.
    Palmu AA; Rinta-Kokko H; Nohynek H; Nuorti JP; Kilpi TM; Jokinen J
    PLoS One; 2017; 12(3):e0172690. PubMed ID: 28249015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.